The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia-Reference-Cited by-同舟云学术

The Long-Term Efficacy and Safety of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Published:2023-11 Issue:9 Volume:2 Page:100648
ISSN:2772-963X
Container-title:JACC: Advances
language:en
Short-container-title:JACC: Advances

Author:

Raal Frederick J.,Rosenson Robert S.^ORCID,Reeskamp Laurens F.^ORCID,Kastelein John J.P.,Rubba Paolo,Duell P. Barton,Koseki Masahiro,Stroes Erik^ORCID,Ali Shazia,Banerjee Poulabi,Chan Kuo-Chen,Khilla Nagwa,McGinniss Jennifer,Pordy Robert,Zhang Yi,Gaudet Daniel

Publisher

Elsevier BV

Reference42 articles.

1. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the consensus panel on familial hypercholesterolaemia of the European Atherosclerosis Society;Cuchel;Eur Heart J,2014

2. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States national health and nutrition examination surveys (NHANES);de Ferranti;Circulation,2016

3. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis;Akioyamen;BMJ Open,2017

4. HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom;France;Atherosclerosis,2016

5. Recommendations for the management of patients with homozygous familial hypercholesterolaemia: overview of a new European Atherosclerosis Society Consensus Statement;Bruckert;Atheroscler Suppl,2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic Monoclonal Antibodies for Metabolic Disorders: Major Advancements and Future Perspectives;Current Atherosclerosis Reports;2024-07-15

2. Evinacumab: Mechanism of action, clinical, and translational science;Clinical and Translational Science;2024-06

3. Improved lipid-lowering treatment and reduction in cardiovascular disease burden in homozygous familial hypercholesterolemia: The SAFEHEART follow-up study;Atherosclerosis;2024-03

4. Novel and Emerging LDL-C Lowering Strategies: A New Era of Dyslipidemia Management;Journal of Clinical Medicine;2024-02-22